Genelux Corporation (NASDAQ:GNLX) Receives Average Rating of “Buy” from Analysts

Genelux Corporation (NASDAQ:GNLX) has been assigned an average recommendation of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $17.75.

Several research firms have weighed in on GNLX. HC Wainwright restated a “buy” rating on shares of Genelux in a report on Wednesday, July 23rd. Wall Street Zen raised shares of Genelux from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Finally, Benchmark decreased their price target on Genelux from $25.00 to $23.00 and set a “speculative buy” rating for the company in a research report on Thursday, May 8th.

Institutional Trading of Genelux

A number of large investors have recently bought and sold shares of the company. Raymond James Financial Inc. lifted its position in shares of Genelux by 22.6% during the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after buying an additional 5,333 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after purchasing an additional 5,596 shares in the last quarter. Beacon Capital Management LLC raised its position in shares of Genelux by 99.8% in the second quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock valued at $55,000 after purchasing an additional 9,550 shares during the period. Falcon Wealth Planning lifted its stake in shares of Genelux by 83.3% during the 2nd quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock valued at $63,000 after buying an additional 10,000 shares in the last quarter. Finally, Private Management Group Inc. bought a new position in Genelux in the 2nd quarter worth approximately $33,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Price Performance

Shares of Genelux stock opened at $3.36 on Thursday. The firm has a market cap of $126.91 million, a price-to-earnings ratio of -3.91 and a beta of -0.32. The stock’s 50-day moving average is $3.23 and its 200 day moving average is $3.24. Genelux has a one year low of $1.95 and a one year high of $5.89.

Genelux (NASDAQ:GNLX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.02. On average, sell-side analysts expect that Genelux will post -0.88 EPS for the current fiscal year.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.